University of Texas Medical Branch, Galveston, TX, U.S.A.
Works
- Luye Life Sciences Expands Global Reach as New Boston R&D Center Opens
- From the Editor: Please Come to Boston
- Svelte Medical Systems Announces Sustained Outstanding Outcomes in Clinical Studies
- Micell Technologies Announces MiStent Achieved Primary Endpoint in All-Comers Randomized Clinical Trial Versus Xience
- Cingulate Therapeutics Initiates First Human Clinical Trial
- Noven Appoints Ralph Lipp, Ph.D., as Vice President and Chief Scientific Officer
- FDA Accepts Genentech’s Biologics License Application for Subcutaneous Formulation of Rituximab
- Windtree Therapeutics Preclinical Study Results Show Potential for KL4 Surfactant as Possible Medical Countermeasure to Radiation Exposure
- Braeburn Pharmaceuticals and Camurus Expand Collaboration and License Agreement to Include New Combination Product for Pain and Nausea
- Ocular Therapeutix™ and Regeneron Enter into Strategic Collaboration to Develop Sustained Release Formulation of Aflibercept for the Treatment of Wet AMD and Other Serious Retinal Diseases
- Plant-Made Biopharmaceuticals Target Dental Plaque, Gum Tissues
- Lupin and MonoSol Rx Announce Licensing Agreement for Multiple Pediatric-Focused Products
- Dicerna Prioritizes Resources to Advance GalXC™ Product Candidates
- Wallace K. Reams, Former President of Aveva Drug Delivery Systems, Joins Transdermal Delivery Solutions Board of Advisors
- DelMar Pharmaceuticals and Accurexa to Collaborate in the Development of a Novel Combination Chemotherapy for the Local Treatment of Brain Cancer
- Crescita Therapeutics™ Inc. Announces Acquisition of INTEGA Skin Sciences
- Caisson Biotech Seeks Buyer for HEPtune® Drug-Delivery Platform
- NLS Pharma Announces Start of Its Phase 2 Trial for Mazindol in Adult ADHD Patients
- Egalet Announces Scientific Presentations at PAINWeek 2016 Meeting
- Nemaura Pharma Limited Awarded the Prestigious 2016 Frost & Sullivan Award for Best Practices in Enabling Technology Leadership in Transdermal Drug Delivery
- Frost & Sullivan Applauds IFP’s Superior Technology Performance and Best Practices in Providing Tailored, ApplicationSpecific Encapsulated Food Ingredients
- Wolfe Laboratories Addresses Rapid Growth with Executive Appointment
- Shasqi Local Drug Activation Technology Provides Improved Drug Efficacy with Minimal Side Effects
- Lannett Announces Receipt of FDA Acceptable Filing Letter for Fentanyl Patch ANDA
- STENTYS Enrolls First Patient in Left Main Clinical Trial
- AngioSoma’s Corporate Focus
- Acorda Presents Phase 1 Data on CVT-427 for Acute Treatment of Migraine at 58th Annual Scientific Meeting of the American Headache Society
- Highland Therapeutics Announces Positive Data from Second Pivotal ADHD Trial for HLD-200
- $1.8 Million Fast-Track NIH SBIR Grant for Manocept™ Immunotherapeutics Evaluation in Kaposi’s Sarcoma Awarded to Navidea
- Nanologica and Alcyone Lifesciences to Collaborate via Licensing Agreement
- NLS Pharma Announces Submission of Investigational New Drug (IND) Application to FDA for Its Controlled-Release Mazindol for the Treatment of Adults with Attention-Deficit/Hyperactivity Disorder (ADHD)
